获批临床 | 诺诚健华新型TYK2抑制剂获批II/III期临床

医药地理
Dec 18, 2025

12月18日,诺诚健华宣布,其自主研发的新型TYK2抑制剂soficitinib(ICP-332)治疗慢性自发性荨麻疹(CSU)获国家药品监督管理局(NMPA)药品审评中心(CDE)批准开展II/III期临床试验。Soficitinib是一款高效、高选择性的新型口服TYK2抑制剂,被开发用于治疗多种T细胞相关的自身免疫性疾病,目前开发的适应症包括特应性皮炎、白癜风、结节性痒疹、荨麻疹等。TYK2...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10